REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL
Journal of the American College of Cardiology（2019）
摘要
LDL cholesterol (LDL-C) reduction with statins and PCSK9 inhibitors reduces risk of myocardial infarction (MI), but effects on specific types of MI are unknown. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab (ALI) with placebo (PBO) in 18924 patients with recent acute coronary syndrome (
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要